Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 14;39(7):586-595.
doi: 10.1093/eurheartj/ehx655.

Quantifying infective endocarditis risk in patients with predisposing cardiac conditions

Affiliations

Quantifying infective endocarditis risk in patients with predisposing cardiac conditions

Martin H Thornhill et al. Eur Heart J. .

Abstract

Aims: There are scant comparative data quantifying the risk of infective endocarditis (IE) and associated mortality in individuals with predisposing cardiac conditions.

Methods and results: English hospital admissions for conditions associated with increased IE risk were followed for 5 years to quantify subsequent IE admissions. The 5-year risk of IE or dying during an IE admission was calculated for each condition and compared with the entire English population as a control. Infective endocarditis incidence in the English population was 36.2/million/year. In comparison, patients with a previous history of IE had the highest risk of recurrence or dying during an IE admission [odds ratio (OR) 266 and 215, respectively]. These risks were also high in patients with prosthetic valves (OR 70 and 62) and previous valve repair (OR 77 and 60). Patients with congenital valve anomalies (currently considered 'moderate risk') had similar levels of risk (OR 66 and 57) and risks in other 'moderate-risk' conditions were not much lower. Congenital heart conditions (CHCs) repaired with prosthetic material (currently considered 'high risk' for 6 months following surgery) had lower risk than all 'moderate-risk' conditions-even in the first 6 months. Infective endocarditis risk was also significant in patients with cardiovascular implantable electronic devices.

Conclusion: These data confirm the high IE risk of patients with a history of previous IE, valve replacement, or repair. However, IE risk in some 'moderate-risk' patients was similar to that of several 'high-risk' conditions and higher than repaired CHC. Guidelines for the risk stratification of conditions predisposing to IE may require re-evaluation.

Keywords: Antibiotic prophylaxis; Guidelines; Incidence; Infective endocarditis; Predisposing conditions; Prevention; Risk; Risk quantification; Risk stratification.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incidence of infective endocarditis in England from January 2000 to March 2015. (A) Incidence of infective endocarditis admissions. (B) Incidence of infective endocarditis admissions where the patient dies during the admission.
Figure 2
Figure 2
Five-year risk (odds) of developing infective endocarditis or dying during an infective endocarditis admission in different cardiac conditions. *Excluding recurrent infective endocarditis within 180 days of the original episode.
Figure 3
Figure 3
Five-year risk (odds) of developing infective endocarditis or dying during an infective endocarditis admission stratified by age and gender. Gender reference population = female, age reference population = 50–59 years.
Figure 4
Figure 4
The Kaplan–Meier survival curves for infective endocarditis-free survival (AC) and death during an infective endocarditis admission-free survival (DF), for each condition. These demonstrate the curves for patients with ‘high risk’ (A and D), ‘moderate risk’ (B and E) and ‘unknown risk’ (C and F) as defined in the ‘Methods’ and by the European Society for Cardiology and American Heart Association (see Supplementary material online, Table S1). For scale and ease of comparison, the previous infective endocarditis population (the highest risk condition) is included in each panel. **Infective endocarditis reoccurrence within 180 days of the original episode has been excluded in the group with previous infective endocarditis. CHC, congenital heart condition; VAD, ventricular assist device; NNH, 5-year number needed to harm; NC, not calculable.

Comment in

References

    1. Cahill TJ, Prendergast BD.. Infective endocarditis. Lancet 2016;387:882–893. - PubMed
    1. Hoen B, Duval X.. Infective endocarditis. N Engl J Med 2013;369:785. - PubMed
    1. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL.. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075–3128. - PubMed
    1. National Institute for Health and Care Excellence (NICE). Prophylaxis against infective endocarditis. http://www.nice.org.uk/guidance/cg64/chapter/Recommendations (1 November 2017). - PubMed
    1. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT.. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736–1754. - PubMed

Publication types

MeSH terms